feedback

Biological Researcher (SME Innovation Associate): Molecular Diagnostics

Lig Biowise

Manchester, United Kingdom

A newly appointed Biological Researcher (SME Innovation Associate) would be working with a team of molecular biologists and medical scientists to develop a new rapid diagnostic system for bacterial infections. Magnetic nanoparticles, coated with oxidised graphene will be used to provide a unique functional surface for conjugating pathogen-specific antibodies in order to target and isolate microbes. In situ amplification of pathogen DNA will then follow to facilitate a sensitive, simple and rapid diagnosis. The method will directly detect pathogens, providing more accurate results than the immunoassay methods currently available to detect infections, which are based on the detection of serum proteins. It is envisaged that this platform of pathogen-specific, antibody-conjugated nanoparticles will become the core technology for future precision treatments of microbial infections.

This advertised position is to work on two key stages of product development:

  • Selection and conjugation of pathogen-specific antibodies onto the surface of the graphene oxide-coated nanoparticles;
  • Design of pathogen-specific primers and development of the amplification reaction and detection system.

Skills/Qualifications:

Applicants must possess a PhD (or equivalent) in molecular biology or related field and an undergraduate degree in biological sciences. Knowledge of nanoparticle conjugation, targeted drug therapy and medical diagnostics is an advantage. A technical and professional training plan is in place for candidates, if needed.

Specific Requirements:

Due to the conditions of the research grant, at the time of recruitment, candidates must have not resided or carried out their main activity (work, studies, etc.) in the UK for more than 12 months in the 3 years immediately before the start date.

Closing date: 16/07/2017

Apply Now

© EuroJobsites

This website uses cookies to make your experience better. Continued use of this website means you accept our cookie policy.  Accept Cookies